Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 3—March 2012


Community-associated Clostridium difficile Infections, Monroe County, New York, USA

Ghinwa DumyatiComments to Author , Vanessa Stevens, George E. Hannett, Angela D. Thompson, Cherie Long, Duncan MacCannell, and Brandi Limbago
Author affiliations: University of Rochester, Rochester, New York, USA (G. Dumyati, V. Stevens); State University of New York at Buffalo, Buffalo, New York, USA (V. Stevens); New York State Department of Health, Albany, New York, USA (G.E. Hannett); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.D. Thompson, C. Long, D. MacCannell, B. Limbago)

Main Article

Table 6

Antimicrobial drug MICs for NAP 1/toxinotype III strains and other strains from case-patients with CDI, Monroe County, New York, USA, March 1–August 31, 2008*

Drug NAP1/toxinotype III, μg/mL
Other strains, μg/mL
MIC50 MIC90 Range MIC50 MIC90 Range
Clindamycin <2 >32 <2 to>32 <2 >32 <2 to >32
Levofloxacin >32 >32 <2 to >32 4 >32 <2 to >32
Moxifloxacin 16 >32 <2 to >32 <2 32 <2 to >32
Metronizadole 2 4 <0.5 to 4 <0.5 2 <0.5 to 2
Vancomycin 1 2 <0.5 to 2 1 2 <0.5 to 2

*NAP, North American pulsed-field; CDI, Clostridium difficile infection. Clinical and Laboratory Standards Institute interpretive criteria (sensitive/ intermediate/resistant): clindamycin: <2/4/>8 μg/mL; levofloxacin: not available; moxifloxacin: <2/4/>8 μg/mL; metronidazole: <8/16/>32 μg/mL; vancomycin: not available.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO